<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00656058</url>
  </required_header>
  <id_info>
    <org_study_id>080097</org_study_id>
    <secondary_id>08-C-0097</secondary_id>
    <nct_id>NCT00656058</nct_id>
  </id_info>
  <brief_title>Montelukast to Treat Bronchiolitis Obliterans</brief_title>
  <official_title>Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic or Autologous Stem Cell Transplantation in Children and Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      Bronchiolitis obliterans is a form of chronic graft-versus-host disease (GVHD) that sometimes
      develops after stem cell transplantation (SCT) or bone marrow transplantation (BMT).

      In bronchiolitis obliterans, immune cells that normally fight infections attack the lungs of
      the transplant recipient, causing destruction of lung tissue and fibrosis (scarring). When
      fibrosis develops, the lungs cannot work properly.

      Montelukast (Singulair) is a drug that has been used for many years to treat asthma. Its use
      as a treatment for bronchiolitis obliterans is experimental.

      Objectives:

      To see if montelukast improves or stabilizes lung function in patients who develop
      bronchiolitis obliterans after BMT or SCT.

      To assess the safety of montelukast in patients with bronchiolitis obliterans after BMT or
      SCT

      To see if montelukast affects the cells that damage the lungs.

      To see if montelukast improves other forms of chronic GVHD, quality of life, and overall
      survival in patients with bronchiolitis obliterans after BMT or SCT.

      Eligibility:

      Patients 6 years of age and older with bronchiolitis obliterans following stem cell
      transplantation.

      Design:

      Patients take one montelukast tablet daily for 6 months and undergo the following procedures
      during this period:

        -  Lung function tests. The patient breathes into a machine that measures the amount of air
           that goes into and out of the lungs. This test is done once a month for 3 months, then
           at 6 months, 12 months and 24 months.

        -  Medical history and physical examination at the study site about every 3 months for the
           first year of the study and then at 12 months and 24 months. Patients also have physical
           examinations monthly for the first 6 months at their primary doctors office. Tests may
           include blood and urine tests, chest computed tomography (CT) scans, echocardiogram
           (heart ultrasound), 2- and 6-minute walk tests, and quality-of-life questionnaires.

        -  Bronchoalveolar lavage in patients 18 years of age and older. The subject s mouth, nose
           and airways are numbed with lidocaine. Some patients may need sedation or anesthesia for
           the procedure. A tube (bronchoscope) is then passed through the nose into the airway,
           and a small amount of fluid is put into the lung. The fluid is then removed and tested
           for infections or other lung problems.

        -  Apheresis to collect white blood cells. Whole blood is collected through a tube inserted
           into a vein in the arm. The white cells are extracted in a cell separator machine, and
           the rest of the blood is returned to the body through a tube placed in a vein in the
           other arm. The cells are used to study GVHD and bronchiolitis obliterans.

        -  Patients who wish to continue montelukast therapy after 6 months may do so under the
           care of their primary doctor, if both agree to the continuation....
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Bronchiolitis obliterans (BO) is an insidious disease with high mortality following
      allogeneic blood or marrow transplantation (BMT). There are no consistently effective
      treatments for BO following BMT and the pathogenesis is largely unknown.

      The mechanisms underlying similar immune-mediated lung destructive processes are better
      elucidated. Rejection following allogeneic lung transplantation and scleroderma lung disease
      result from analogous immunologically mediated destruction of lung tissue leading to similar
      pathologic and clinical presentations to post-BMT BO.

      Increased leukotriene production has recently been implicated in the development of both
      post-lung transplant BO and scleroderma lung disease in animal models and patient studies.

      Montelukast (singulair) is an approved, well-tolerated, oral agent that inhibits leukotriene
      action in lung inflammation. This agent has been extensively used in children and adults to
      treat asthma with an excellent safety profile.

      Objectives:

      To evaluate if montelukast stabilizes or improves pulmonary function in patients with BO
      after BMT using forced expiratory volume 1 (FEV-1) changes as primary endpoints, and oxygen
      saturation, pulmonary function test (PFT) parameters (forced expiratory flow (FEF) 25-75,
      residual volume (RV) and RV/forced vital capacity (FVC), carbon monoxide diffusing capacity
      (DLC02), FEV-1/FVC, FEV-1/slow vital capacity (SVC) ratio), and timed walk tests as secondary
      endpoints.

      To evaluate the safety of montelukast in the population of patients with BO after BMT.

      To investigate if leukotriene elevation contributes to the pathogenesis of BO after BMT by
      measuring leukotriene levels of the blood, urine, and bronchoalveolar lavage (BAL), and
      leukotriene surface receptor expression on immune cells before and after montelukast
      administration.

      To determine if montelukast improves other chronic graft versus host disease (cGVHD)
      manifestations, quality of life, and overall survival.

      Eligibility:

      Patients greater than or equal to 6 years old with bronchiolitis obliterans following stem
      cell transplantation for any disease indication may be enrolled.

      Design:

      This is a prospective phase II study, the primary aim of which is to assess whether
      montelukast improves or stabilizes the pulmonary function of patients with BO after BMT.

      Primary outcome data will be analyzed in 2 ways. 1) The proportion of patients with stable or
      improved percent predicted of FEV-1 will be compared against benchmark data obtained from a
      literature review. 2) The slope of FEV-1 before and after the introduction of montelukast
      will be compared.

      Pediatric and adult patients with BO following BMT will receive approved doses of montelukast
      continuously.

      The planned length of the study would be 2 years per patient with primary endpoint at 6
      months, permitting sufficient time to determine safety and meet other endpoints.

      This phase II trial will be conducted at 2 institutions: National Institutes of Health (NIH)
      and Fred Hutchinson Cancer Research Center. Forty-five patients will be enrolled on this
      trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 17, 2008</start_date>
  <completion_date type="Actual">February 22, 2018</completion_date>
  <primary_completion_date type="Actual">May 2, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Stable or Improved Predicted Forced Expiratory Volume 1 (FEV-1) With Published Literature</measure>
    <time_frame>180 days</time_frame>
    <description>Responsive disease (RD) will be defined as â‰¥15% absolute improvement in the percentage predicted FEV-1. Progressive disease (PD) will be defined as &gt;15% decrease in FEV-1 documented on 2 pulmonary function test (PFT) evaluations greater than 2 weeks apart. Stable disease (SD) will be defined as &lt;15% change in the absolute FEV-1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Improved, Stable or Declined Forced Expiratory Volume 1 (FEV-1) Slope at 6 Months</measure>
    <time_frame>180 days</time_frame>
    <description>FEV-1 slope of decline was generated using regression line of FEV-1 value vs. days post hematopoietic stem cell transplant. Responsive disease (RD) for the slope of FEV-1 change will be an increase in the slope of absolute FEV-1. Progressive disease (PD) for the slope of FEV-1 change will be a decrease in the slope of absolute FEV-1. Stable disease (SD) for the slope of FEV-1 change will be a 0 change in FEV-1 slope.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Date treatment consent signed to date off study, approximately 71 months and 17 days</time_frame>
    <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume 1 (FEV-1)/Vital Capacity (VC)</measure>
    <time_frame>Baseline</time_frame>
    <description>Pulmonary function test performed for eligibility and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Overall 2-Year Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of participants alive at 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Non-Infected Participants at Baseline With Cysteinyl Leukotriene Receptor Expression on Cluster of Differentiation (CD4) and CD8 T Cells, Granulocytes, and Eosinophils in Bronchoalveolar Lavage (BAL) Fluid</measure>
    <time_frame>Day 1 of study</time_frame>
    <description>Fluid from the bronchoalveolar lavage in adult participants (pediatric optional) will be collected and sent to the lab to be evaluated for infectious diseases by flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Bronchiolitis Obliterans</condition>
  <condition>Chronic Graft Versus Host Disease</condition>
  <condition>Leukotriene</condition>
  <condition>Montelukast</condition>
  <condition>Stem Cell Transplant</condition>
  <arm_group>
    <arm_group_label>Montelukast to Treat Bronchiolitis Obliterans</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Montelukast for the treatment of BO following allogeneic or autologous stem cell transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Singulair (Montelukast Sodium)</intervention_name>
    <description>Singulair (Montelukast Sodium):5-10 mg (weight based dosing) by mouth (PO) hour of sleep (HS)</description>
    <arm_group_label>Montelukast to Treat Bronchiolitis Obliterans</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Age greater than 6 years old.

        Diagnosis of bronchiolitis obliterans after allogeneic or autologous stem cell transplant.
        The criteria will be based on the definitions created by the National Institutes of Health
        (NIH) consortium on chronic graft versus host disease (cGVHD). As part of these criterion,
        for patients without pathologic evidence of BO, one other sign of chronic GVHD must be
        present. For diagnosis of cGVHD, a minimum of the following must be present: 1) a process
        distinct from that diagnosed as acute GVHD, 2) the presence of a diagnostic sign or a
        distinctive sign supported by another clinical or laboratory test, and 3) the exclusion of
        other pathologies (i.e. recurrent cancer, drug reaction or infection (see Appendix 5a for a
        list of diagnostic signs.). To meet criteria for a diagnosis of bronchiolitis obliterans,
        patients must fulfill all 3 criteria. Prior lung tissue biopsy will be analyzed and
        confirmed to show evidence of bronchiolitis obliterans by the National Cancer Institute
        (NCI) Laboratory of Pathology if available. If tissue is not available for confirmation, a
        new biopsy will not be performed.

        For bronchiolitis obliterans:

          1. Forced expiratory volume 1 (FEV1) less than or equal to 75 percent of predicted by
             pulmonary function evaluation for height and weight.

          2. Evidence of air-trapping or small airway thickening or bronchiectasis on high
             resolution chest computed tomography (CT) and residual volume (RV) or RV/forced vital
             capacity (FVC) greater than 120 percent and evidence of chronic GVHD of another organ,
             OR FEV1/ vital capacity (slow or forced VC whichever is larger) ratio less than 5
             percent of predicted for age or less than 0.7, OR pathologic evidence of bronchiolar
             inflammation and obstruction of the lumen consistent with a diagnosis of BO. Pulmonary
             function tests will utilize body plethysmography not helium studies for pertinent
             values when there is a discrepancy if available.

          3. Absence of active infection with appropriate investigation of any clinical symptoms to
             include radiographic, microbiologic, and pathologic studies as determined by the PI or
             LAI.

             Patients must also have 2 PFT measurements with documented FEV1 values greater than 3
             months apart to calculate the entry FEV1 slope. All available prior PFTs will be
             utilized for baseline slope calculation. For adult patients, the absolute FEV1 will be
             utilized for slope calculation; for pediatric patients, the percent predicted will be
             used. For patients enrolled after an acute decline following BMT without 2 post-BMT
             values greater than 3 months apart, the pre-BMT value may be utilized as the first
             value and the entry PFT value may be the second for the slope calculation. The
             baseline and 6th-cycle PFT should be done at the accruing site.

             Prior therapy: For patients with a chronic diagnosis of BO who have been on
             treatments, any prior therapy that has been administered chronically for &gt; 3 months
             will be acceptable for enrollment as long as the patient has not demonstrated
             consistent improvement attributed to these agents in a one month (or more) period of
             observation preceding enrollment. For patients on steroids, a steroid burst exceeding
             and increase of one half mg/kg/day will be considered for the start of the 3 month
             monitoring period. Notably, documented intercurrent infections that are treated with
             antimicrobials that result in improvements to, but not above previous baselines will
             not be considered an improvement attributable to immunosuppressive therapy. Patients
             who have had consistent improvements in the months preceding trial entry will not be
             eligible since there will be no way to discern improvement due to montelukast versus
             another therapy. Alternatively, a patient with a new diagnosis of bronchiolitis
             obliterans characterized by a new decrease in FEV1 is also eligible for this study.
             Notably, patients who have received bronchodilators or other pulmonary therapies may
             be included in this study as long as montelukast is not part of this regimen.

             Performance status: Karnofsky or Lansky performance status greater than or equal to 40
             percent (Appendix 1).

             Ability to give informed consent. For patients less than 18 years of age, their legal
             guardian must give informed consent. Pediatric patients will be included in an age
             appropriate discussion in accordance with NIH guidelines or participating
             institutional guidelines.

             Hepatic function: Patients must have evidence of adequate liver function prior to
             enrollment defined by total bilirubin less than 3 times the upper limit of normal and
             transaminases less than 5 times the upper limit of normal for age appropriate indices.

             Cardiac function: Patients must have evidence of adequate cardiac function prior to
             enrollment defined by ejection fraction greater than 25 percent performed within the
             last 6 months at NIH and absence of symptoms of cardiac disease at FHCRC, JHH, or
             Hackensack.

             Pulmonary function: Patients must have an FEV1 greater than or equal to 20 percent
             predicted for inclusion in this study.

             EXCLUSION CRITERIA:

             Underlying disease status: Patients with tumor burden greater than minimal residual
             disease (i.e. tumor burden that can only be detected by molecular methods) would be
             excluded from this study.

             Prior post-transplant treatment with montelukast or zakirlukast within the past 2
             months and total duration of therapy does not exceed 3 months.

             Clinically significant systemic illness with manifestations of significant organ
             dysfunction which in the judgment of Principal or Associate Investigator would render
             the patient unlikely to tolerate the protocol therapy or complete the study.

             Patients must have been on their current cGVHD therapeutic regimen for at least 3
             months with stable or decreasing FEV1 to be eligible for this trial. Any patient who
             has been on a therapy for less than 3 months for cGVHD will need to be monitored for 3
             months without improvement in FEV1 prior to enrollment.

             Ventilated patients are excluded.

             Patients taking rifampin or phenobarbital as these medications alter the metabolism of
             montelukast.

             Patients taking greater than one age-appropriate dose of ibuprofen or aspirin
             containing products per day that inhibit cyclooxygenase will be excluded from this
             trial. The acceptable upper limit for adult daily doses of aspirin is 650mg/day and
             800mg/day of ibuprophen. For children, the acceptable upper limit of ibuprophen is
             pediatric dose per day (less than 10 mg per kg to a maximum of 800 mg). Children
             should not take aspirin due to risk of Reye's syndrome unless specifically prescribed
             by their physician.

             Patients with a history of allergy to montelukast.

             Pregnant females and nursing mothers will be excluded from this trial due to unknown
             risks to the developing fetus. While on study, patients of child-bearing potential
             must be able to consent to utilize effective birth control measures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald E Gress, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2008-C-0097.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Williams KM, Hnatiuk O, Mitchell SA, Baird K, Gadalla SM, Steinberg SM, Shelhamer J, Carpenter A, Avila D, Taylor T, Grkovic L, Pulanic D, Comis LE, Blacklock-Schuver B, Gress RE, Pavletic SZ. NHANES III equations enhance early detection and mortality prediction of bronchiolitis obliterans syndrome after hematopoietic SCT. Bone Marrow Transplant. 2014 Apr;49(4):561-6. doi: 10.1038/bmt.2013.222. Epub 2014 Jan 13.</citation>
    <PMID>24419526</PMID>
  </reference>
  <results_reference>
    <citation>Oral presentation: &quot;Interim Analysis of a Phase II Trial of Montelukast for the Treatment of Bronchiolitis Obliterans Syndrome after HSCT reveal Immunobiology of Disease American Society of Blood and Marrow Transplantation 2013</citation>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2008</study_first_submitted>
  <study_first_submitted_qc>April 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2008</study_first_posted>
  <results_first_submitted>August 29, 2016</results_first_submitted>
  <results_first_submitted_qc>August 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2016</results_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Ronald Gress, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Leukotriene</keyword>
  <keyword>Chronic Graft-Versus-Host Disease</keyword>
  <keyword>Montelukast</keyword>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>Bronchiolitis Obliterans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Montelukast to Treat Bronchiolitis Obliterans</title>
          <description>Montelukast for the treatment of BO following allogeneic or autologous stem cell transplant.
Singular (Montelukast Sodium): Singular (Montelukast Sodium):5-10 mg (weight based dosing) PO HS</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Montelukast to Treat Bronchiolitis Obliterans</title>
          <description>Montelukast for the treatment of BO following allogeneic or autologous stem cell transplant.
Singular (Montelukast Sodium): Singular (Montelukast Sodium):5-10 mg (weight based dosing) PO HS</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.29" spread="15.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Stable or Improved Predicted Forced Expiratory Volume 1 (FEV-1) With Published Literature</title>
        <description>Responsive disease (RD) will be defined as â‰¥15% absolute improvement in the percentage predicted FEV-1. Progressive disease (PD) will be defined as &gt;15% decrease in FEV-1 documented on 2 pulmonary function test (PFT) evaluations greater than 2 weeks apart. Stable disease (SD) will be defined as &lt;15% change in the absolute FEV-1.</description>
        <time_frame>180 days</time_frame>
        <population>No data is available for the one missing participant.</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast to Treat Bronchiolitis Obliterans</title>
            <description>Montelukast for the treatment of BO following allogeneic or autologous stem cell transplant.
Singular (Montelukast Sodium): Singular (Montelukast Sodium):5-10 mg (weight based dosing) PO HS</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stable or Improved Predicted Forced Expiratory Volume 1 (FEV-1) With Published Literature</title>
          <description>Responsive disease (RD) will be defined as â‰¥15% absolute improvement in the percentage predicted FEV-1. Progressive disease (PD) will be defined as &gt;15% decrease in FEV-1 documented on 2 pulmonary function test (PFT) evaluations greater than 2 weeks apart. Stable disease (SD) will be defined as &lt;15% change in the absolute FEV-1.</description>
          <population>No data is available for the one missing participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Increased 5-13% of predicted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Declined</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Improved, Stable or Declined Forced Expiratory Volume 1 (FEV-1) Slope at 6 Months</title>
        <description>FEV-1 slope of decline was generated using regression line of FEV-1 value vs. days post hematopoietic stem cell transplant. Responsive disease (RD) for the slope of FEV-1 change will be an increase in the slope of absolute FEV-1. Progressive disease (PD) for the slope of FEV-1 change will be a decrease in the slope of absolute FEV-1. Stable disease (SD) for the slope of FEV-1 change will be a 0 change in FEV-1 slope.</description>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Montelukast to Treat Bronchiolitis Obliterans</title>
            <description>Montelukast for the treatment of BO following allogeneic or autologous stem cell transplant.
Singular (Montelukast Sodium): Singular (Montelukast Sodium):5-10 mg (weight based dosing) PO HS</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improved, Stable or Declined Forced Expiratory Volume 1 (FEV-1) Slope at 6 Months</title>
          <description>FEV-1 slope of decline was generated using regression line of FEV-1 value vs. days post hematopoietic stem cell transplant. Responsive disease (RD) for the slope of FEV-1 change will be an increase in the slope of absolute FEV-1. Progressive disease (PD) for the slope of FEV-1 change will be a decrease in the slope of absolute FEV-1. Stable disease (SD) for the slope of FEV-1 change will be a 0 change in FEV-1 slope.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Declined</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
        <time_frame>Date treatment consent signed to date off study, approximately 71 months and 17 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Montelukast to Treat Bronchiolitis Obliterans</title>
            <description>Montelukast for the treatment of BO following allogeneic or autologous stem cell transplant.
Singular (Montelukast Sodium): Singular (Montelukast Sodium):5-10 mg (weight based dosing) PO HS</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume 1 (FEV-1)/Vital Capacity (VC)</title>
        <description>Pulmonary function test performed for eligibility and baseline.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Montelukast to Treat Bronchiolitis Obliterans</title>
            <description>Montelukast for the treatment of BO following allogeneic or autologous stem cell transplant.
Singular (Montelukast Sodium): Singular (Montelukast Sodium):5-10 mg (weight based dosing) PO HS</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume 1 (FEV-1)/Vital Capacity (VC)</title>
          <description>Pulmonary function test performed for eligibility and baseline.</description>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.29" upper_limit="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Overall 2-Year Survival</title>
        <description>Percentage of participants alive at 2 years.</description>
        <time_frame>2 years</time_frame>
        <population>This is a multicenter study and the number analyzed reflect data for evaluable subjects enrolled at the National Institutes of Health only.</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast to Treat Bronchiolitis Obliterans</title>
            <description>Montelukast for the treatment of BO following allogeneic or autologous stem cell transplant.
Singular (Montelukast Sodium): Singular (Montelukast Sodium):5-10 mg (weight based dosing) PO HS</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Overall 2-Year Survival</title>
          <description>Percentage of participants alive at 2 years.</description>
          <population>This is a multicenter study and the number analyzed reflect data for evaluable subjects enrolled at the National Institutes of Health only.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Non-Infected Participants at Baseline With Cysteinyl Leukotriene Receptor Expression on Cluster of Differentiation (CD4) and CD8 T Cells, Granulocytes, and Eosinophils in Bronchoalveolar Lavage (BAL) Fluid</title>
        <description>Fluid from the bronchoalveolar lavage in adult participants (pediatric optional) will be collected and sent to the lab to be evaluated for infectious diseases by flow cytometry</description>
        <time_frame>Day 1 of study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Montelukast to Treat Bronchiolitis Obliterans</title>
            <description>Montelukast for the treatment of BO following allogeneic or autologous stem cell transplant.
Singular (Montelukast Sodium): Singular (Montelukast Sodium):5-10 mg (weight based dosing) PO HS</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Non-Infected Participants at Baseline With Cysteinyl Leukotriene Receptor Expression on Cluster of Differentiation (CD4) and CD8 T Cells, Granulocytes, and Eosinophils in Bronchoalveolar Lavage (BAL) Fluid</title>
          <description>Fluid from the bronchoalveolar lavage in adult participants (pediatric optional) will be collected and sent to the lab to be evaluated for infectious diseases by flow cytometry</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Date treatment consent signed to date off study, approximately 71 months and 17 days.</time_frame>
      <desc>The serious adverse events while on study are not possibly, probably, or definitely related to montelukast or attributed to research interventions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Montelukast to Treat Bronchiolitis Obliterans</title>
          <description>Montelukast for the treatment of BO following allogeneic or autologous stem cell transplant.
Singular (Montelukast Sodium): Singular (Montelukast Sodium):5-10 mg (weight based dosing) PO HS</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other (gastroenteritis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI::Abdomen NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not associated with CTCAE term::Death NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term::Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other (CMV reactivation)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infection - Other (pneumonia/infection with unknown ANC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infection - Other (sinusitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Upper airway NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC::Colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC::Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC::Urinary tract NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint-effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration::Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Parainfluenza Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>RSV Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria (hives, welts, wheals)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal - Other (Pneumatosis coli)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam)::Oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>(documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)::Lung (pneumonia)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infection - Other (Helicobacter pylori infection)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infection - Other (S. Maltophilia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infection - Other (URI)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infection - Other (Viral infection (evaluated by home physicians))</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infection - Other (fever and URI symptoms)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infection - Other (upper respiratory infection)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Bronchus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Upper airway NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC::Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC::Sinus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>GGT (gamma-Glutamyl transpeptidase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Triglyceride, serum-high (hypertriglyceridemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy)::Extremity-lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pain: joint</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychosis (hallucinations/delusions)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/Genitourinary - Other (interstitial renal fibrosis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory::Lung</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pain::Chest/thorax NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other (URI)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ronald E. Gress</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301-496-1791</phone>
      <email>gressr@dc10a.nci.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

